- Pretreatment positron emission tomography (PET) staging was associated with significantly better OS and lung cancer-specific survival (LCSS) in patients with small-cell lung cancer (SCLC).
Why this matters
- Current guidelines recommend PET/CT for patients with limited-stage SCLC (LS-SCLC) but not extensive-stage (ES-SCLC).
- 10,135 patients from the Department of Veterans Affairs Central Cancer Registry diagnosed with SCLC between 2001 and 2010.
- Funding: None disclosed.
- 3510 patients had LS-SCLC, 6143 had ES-SCLC, and 482 had an unknown stage.
- Median OS increased during the study period overall (6.2 vs 7.9 months; P<.0001 in ls-sclc vs months p=".004)," and es-sclc>
- Median LCSS also improved overall (7.5 vs 8.6 months; P<.0001 in ls-sclc vs months p and es-sclc>
- Pretreatment PET increased from 1.1% in 2001 to 39.2% in 2010, with the greatest increase in LS-SCLC (1.8% to 53.7%).
- Pretreatment PET was independently associated with better OS and LCSS in LS-SCLC (HR, 0.78; 95% CI, 0.68-0.90 and HR, 0.74; 95% CI, 0.63-0.87) and ES-SCLC (HR, 0.69; 95% CI, 0.64-0.75 and HR, 0.70; 95% CI, 0.64-0.76).
- All-veteran population.